RA
Lipum approaches the finish line in the study – last patient recruited
Lipum has recruited all patients with rheumatoid arthritis for the final part of the phase I study with SOL-116. Now all that remains is...
Cyxone's CEO on plans for 2024
Cyxone's CEO Carl-Magnus Högerkorp is interviewed in BioStock's studio...
Ola Sandborgh takes over as CEO of Lipum
Lipum has appointed Ola Sandborgh as new CEO...
Cyxone on the new strategy
Biotechnology company Cyxone recently announced that it is changing its strategy...
Lipum accelerates clinical development
Lipum
Lipum's clinical development journey continues in 2023
2022 was the year when the biopharmaceutical company Lipum...
Lipum exits Q3 as a clinical development company
In Lipum's quarterly report, CEO Einar Pontén says that...
Torgny Stigbrand about the investment in Lipum
In October, Lipum carried out a directed new share issue of...
GSK closes RA project
Yesterday, British pharmaceutical giant GSK announced that they...
All clear for Lipum's study – CMO comments
Recently, Lipum's clinical trial application was approved by the regulatory authorities...
SynAct's CSO on the revision of the nephrology study
In July, SynAct Pharma applied for approval of...
Lipum's work with its Target Product Profile
Developing a so-called Target Product...